Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Abrams

Showing results (51-60 of 371) with videos related to

Pageof 38
Sort By:
Journal of Cannabis Research|July 3, 2021
A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeuticsKevin P Hill, Donald I Abrams
Cancer Cell|April 2, 2021
Redirecting macrophage function to sustain their "defender" antitumor activityStephanie L Tzetzo, Scott I Abrams
Current Opinion in Oncology|September 1, 2007
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy eraMichael J Silverberg, Donald I Abrams
Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1991
CD4+ T lymphocyte-induced target cell detachment. A model for T cell-mediated lytic and nonlytic inflammatory processesS I Abrams, J H Russell
The New England Journal of Medicine|June 8, 2012
What's the alternative?Donald I Abrams, Andrew T Weil
AIDS Clinical Review|January 1, 1992
Burnout among HIV/AIDS health care providers. Helping the people on the frontlinesJ A Macks, D I Abrams
Lancet (London, England)|June 23, 1984
AIDS and parasitismR B Pearce, D I Abrams
Lancet (London, England)|May 24, 1997
Genotypic-resistance assays and antiretroviral therapyS G Deeks, D I Abrams
Seminars in Oncology|June 1, 1987
Alpha interferon therapy of AIDS-associated Kaposi's sarcomaD I Abrams, P A Volberding
Cancer Immunology, Immunotherapy : CII|February 28, 2001
Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinantM Hilburger Ryan, S I Abrams
Pageof 38

Showing results (51-60 of 371) with videos related to

Sort By:
Pageof 38
Journal of Cannabis Research|July 3, 2021
A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeuticsKevin P Hill, Donald I Abrams
Cancer Cell|April 2, 2021
Redirecting macrophage function to sustain their "defender" antitumor activityStephanie L Tzetzo, Scott I Abrams
Current Opinion in Oncology|September 1, 2007
AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy eraMichael J Silverberg, Donald I Abrams
Journal of Immunology (Baltimore, Md. : 1950)|January 15, 1991
CD4+ T lymphocyte-induced target cell detachment. A model for T cell-mediated lytic and nonlytic inflammatory processesS I Abrams, J H Russell
The New England Journal of Medicine|June 8, 2012
What's the alternative?Donald I Abrams, Andrew T Weil
AIDS Clinical Review|January 1, 1992
Burnout among HIV/AIDS health care providers. Helping the people on the frontlinesJ A Macks, D I Abrams
Lancet (London, England)|June 23, 1984
AIDS and parasitismR B Pearce, D I Abrams
Lancet (London, England)|May 24, 1997
Genotypic-resistance assays and antiretroviral therapyS G Deeks, D I Abrams
Seminars in Oncology|June 1, 1987
Alpha interferon therapy of AIDS-associated Kaposi's sarcomaD I Abrams, P A Volberding
Cancer Immunology, Immunotherapy : CII|February 28, 2001
Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinantM Hilburger Ryan, S I Abrams
Pageof 38